Impact of a mobile application (reminder app) on acute toxicity during radiotherapy of head-and-neck cancer – results of a randomized phase III trial (RAREST-02)

Dirk Rades*, Inga Zwaan, Jon Cacicedo, Karl L. Bruchhage, Samer G. Hakim, Denise Olbrich, Steven E. Schild, Soeren Tvilsted, Stefan Janssen

*Corresponding author for this work
11 Citations (Scopus)

Abstract

Background: Radiotherapy of head-and-neck cancer (SCCHN) is often associated with acute toxicity. In a previous trial, daily reminders by staff members to perform skin care resulted in less dermatitis. This randomized trial investigated whether a mobile application can replace these reminders. Methods: Patients were stratified according to tumor site, treatment and center. Fifty-three patients were eligible for per-protocol-set (25 with, 28 without app). Primary endpoint was grade ≥ 2 dermatitis until 60 Gy. Secondary endpoints included dermatitis grade ≥ 2 until end of radiotherapy (EOT), dermatitis grade ≥ 3, and mucositis grade ≥ 2 and ≥ 3. Results: After an interim analysis, the study was terminated (delayed and slow accrual). Until 60 Gy, grade ≥ 2 dermatitis rates were 72% with vs. 82% without app (p = 0.38), grade ≥ 3 dermatitis rates 20% vs. 11% (p = 0.45). Until EOT, grade ≥ 2 and ≥ 3 dermatitis rates were 72% vs. 86% (p = 0.22) and 24% vs. 18% (p = 0.58). Until 60 Gy, grade ≥ 2 and ≥ 3 mucositis rates were 76% vs. 82% (p = 0.58) and 20% vs. 36% (p = 0.20). Until EOT, corresponding mucositis rates were 76% vs. 82% (p = 0.58) and 28% vs. 43% (p = 0.26). Conclusion: Given the limitations of this trial, the reminder app led to non-significant reduction of grade ≥ 2 dermatitis, grade ≥ 2 mucositis and ≥ 3 mucositis. Additional studies are required to define the value of reminder apps during radiotherapy for SCCHN.

Original languageEnglish
Article number989
JournalBMC Cancer
Volume22
Issue number1
ISSN1471-2407
DOIs
Publication statusPublished - 12.2022

Funding

The study is part of the INTERREG-project NorDigHealth. The authors thank all colleagues and project partners for the excellent collaboration. We particularly thank Hannes Köhler and Hagen Schulze from Nextlabel OHG for the reminder app they have developed for this study. Open Access funding enabled and organized by Projekt DEAL. As part of the project NorDigHealth, this trial received funding from the European Regional Development Fund through the Interreg Deutschland-Danmark program, reference: 087–1.1–18. The funding body had no role in designing the study, in collecting, analysing and interpreting the data and in manuscript writing.

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)
  • Centers: University Cancer Center Schleswig-Holstein (UCCSH)

DFG Research Classification Scheme

  • 2.22-30 Radiology

Fingerprint

Dive into the research topics of 'Impact of a mobile application (reminder app) on acute toxicity during radiotherapy of head-and-neck cancer – results of a randomized phase III trial (RAREST-02)'. Together they form a unique fingerprint.

Cite this